These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1578945)

  • 1. Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Sarno E; Frei E
    Leukemia; 1992; 6 Suppl 2():66-7. PubMed ID: 1578945
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
    Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
    Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
    Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
    N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy for acute myelogenous leukemia.
    Kalaycio M
    Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
    [No Abstract]   [Full Text] [Related]  

  • 7. Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
    Reiffers J; Stoppa AM; Rigal-Huguet F; Michallet M; Marit G; Blaise D; Attal M; Corront B; Cony-Makhoul P; Gastaut JA
    Leukemia; 1992; 6 Suppl 2():124-6. PubMed ID: 1578913
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
    Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
    Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
    [No Abstract]   [Full Text] [Related]  

  • 9. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
    Kolitz JE; George SL; Baer MR; Lee EJ; Bloomfield CD; Larson RA;
    Ann Hematol; 2004; 83 Suppl 1():S103-4. PubMed ID: 15124695
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance.
    Curtis JE; Messner HA; Minden MD; Lipton JH; Lockwood GA; Tritchler DL; McCulloch EA
    Leukemia; 1992 Nov; 6(11):1192-8. PubMed ID: 1434804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
    Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
    Ter Arkh; 1994; 66(7):11-7. PubMed ID: 7985120
    [No Abstract]   [Full Text] [Related]  

  • 14. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic results in acute myeloid leukemias in elderly patients].
    Parovichnikova EN; Savchenko VG; Isaev VG; Tikhonova LIu; Sarycheva TG; Kulikov SM
    Ter Arkh; 1992; 64(8):87-9. PubMed ID: 1440406
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
    Damon LE; Rugo HS; Ries CA; Linker CA
    Leukemia; 1994 Apr; 8(4):535-41. PubMed ID: 8152248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.